| Identification | Back Directory | [Name]
SK-216 | [CAS]
654080-03-2 | [Synonyms]
SK-216
SK216,SK 216
SK216.Plasminogen activator inhibitor-1 (PAI-1) inhibitor
2-[5-[[6-[5-(1,1-Dimethylethyl)-2-benzoxazolyl]-2-naphthalenyl]oxy]pentyl]propanedioic acid disodium salt | [Molecular Formula]
C29H32NNaO6 | [MDL Number]
MFCD17167041 | [MOL File]
654080-03-2.mol | [Molecular Weight]
513.57 |
| Chemical Properties | Back Directory | [Melting point ]
>300°C | [storage temp. ]
room temp | [solubility ]
Water (Slightly, Heated) | [form ]
powder | [color ]
white to beige | [Water Solubility ]
Soluble to 5 mM in water with gentle warming |
| Hazard Information | Back Directory | [Uses]
SK-216 is a plasminogen activator inhibitor-1 (PAI-1) that limits tumor progression and angiogenesis, a therapeutic target in the management of malignancy. | [Biological Activity]
SK-216 is an orally active potent and selective inhibitor of Plasminogen activator inhibitor-1 (PAI-1) th at inhibits tumor progression and angiogenesis. SK-216 inhibits migration and tube formation of cultured human umbilical vein endothelial cells induced by various angiogenic factors. SK-116 prevents a formation of gastro-intestinal polyps in Min mice. | [in vivo]
SK-216 (i.p., 6.6 μg/200 μL in PBS, once every 3 days) inhibits lung metastasis of human osteosarcoma cells, but not tumor growth in primary tumors in male athymic nude mice with 143B-Luc cell model[1].
| Animal Model: | 5-6-week-old male athymic nude mice with 143B-Luc cell[1] | | Dosage: | 6.6 μg/200 μL in PBS | | Administration: | i.p., once every 3 days | | Result: | Resulted in a significant reduction in PAI-1 expression levels in primary lesions in mice. |
| [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|